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  Recent studies have revealed that the neural stem cells (NSCs), which possess the ability of proliferation and 
differentiation into neurons and glial cells, exist in the mammalian adult brain, including the anterior subventricular 
zone (aSVZ) and the hippocampal dentate gyrus. The NSCs in the dentate gyrus are known to lie along the border 
between the hilus and the granule cell layer (GCL), so called subgranular zone (SGZ), and to migrate into the GCL 
and to differentiate into the glial cells and the granule cells, resulting in the generation of several thousands of 
newborn cells each day. Furthermore, the small portion of newly generated neurons is reported to be integrated into 
existing neuronal circuitries. The role of neurogenesis in the dentate gyrus is still unclear, however, several lines 
of evidence suggest its involvement in the learning and memory and neuropsychiatric disorders. Interestingly, the 
proliferation and differentiation of the NSCs as well as the survival of newborn cells are dynamically influenced 
by a certain type of brain injuries such as ischemia, epilepsy or neuroinflammation. Thus, the identification of 
the signaling molecules regulating NSC activity may contribute not only to the understanding of the neurogenesis 
mechanisms but also toward the development of new therapy against neural death. 
  Recently, lipopolysaccharide (LPS), a bacterial endotoxin, is reported to modulate the neurogenesis in the dentate 
gyms of mammalian brain by causing the neuroinflammation including the activation of microglial cells. It has 
been demonstrated that the peripheral administration of LPS diminishes the neurogenesis in the hippocampal 
dentate gyms via the activation of microglial cells in the brain. The neurogenesis consists of the proliferation and 
the neural differentiation of the NSCs and the survival of newborn cells. However, it is not clear which processes 
of the neurogenesis are diminished by LPS. Also, the molecular mechanisms underlying the impairment of the 
neurogenesis elicited by systemic treatment with LPS is not fully understood. In general, the central and the 
peripheral actions of LPS are mediated or enhanced by the arachidonic acid cascade. In this cascade, two types of 
cyclooxygenase (COX),  COX-1 and COX-2, act as rate-limiting enzymes catalyzing the conversion of arachidonic 
acid to prostaglandin H2 and several prostanoids such as prostaglandin E2  (PGE2),  prostaglandinF2a, prostaglandin 
 12, prostaglandin  D, (PGD2) and thromboxane A, are known to be produced from prostaglandin  H2 by specific 
synthetase. In addition, LPS is known to increase the expression level of COX-2 not only in the peripheral tissues 
but also in the brain. On the other hand, COX and some prostanoids are reported to involve the modulation of the 
neurogenesis in the dentate gyms by the ischemia and the epilepsy. However, little is known about the involvement 
of COX in the modulatory actions of LPS on the neurogenesis in adult brains. This study was, therefore, designed 
to determine which processes of the neurogenesis in the adult mouse dentate gyms are affected by LPS treatment 
and to clarify the involvement of COX in the LPS actions using the bromodeoxyuridine (BrdU)-pulse chase method 
and terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) staining. 
 Firstly, the temporal effect of LPS was assayed at the time point of 2 hrs, 7 and 21 days after its injections. The 
2 hrs time point evaluates the proliferation process; 7 and 21 days to differentiation and survival, respectively.
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LPS failed to affect the number of BrdU-labeled cells in the dentate gyrus 2 hrs after BrdU injection, indicating 
no effects of LPS on the proliferation of the NSCs. On the other hand,  LPS reduced the number of BrdU-labeled 
cells in the dentate gyrus 7 days after BrdU injection in a dose-dependent manner. Twenty-one days after  BrdU 
injection, the absolute number of BrdU-labeled cells in the dentate gyrus was lower than that at 7 days after BrdU 
injection. To confirm whether LPS acts on survival of NSCs, a staining of apoptotic cells was used. The systemic 
injection of  LPS at 1 mg/kg significantly increased the number of TUNEL-positive cells in the dentate gyrus 5 days 
after the treatment, suggesting that LPS impaired the survival of newborn cells derived from the NSCs. 
 To investigate which fate of the NSCs could be affected by  LPS, the proportion of BrdU-labeled cells co-
expressing the immature neuronal marker DCX, the mature  neuronal marker NeuN or the astrocyte marker GFAP 
in the dentate gyms was examined 7 and 21 days after BrdU injection. We also found that the proportion of cells 
committed to neural lineage (DCX- and NeuN-positive) and astroglial lineage (GFAP-positive) was not changed 
by LPS treatment, suggesting that  LPS does not affect the differentiation process itself. LPS, therefore, might 
reduce the survival of immature cells that do not undergo the  fate-determination. Alternatively, we cannot rule 
out the  possibility that LPS decreases the survival of neuron-restricted progenitor cells and astrocyte-restricted 
progenitor cells in the same degree. The NSCs were treated in vitro with LPS (0.01, 0.1 and 1  µg/ml) for 24  hrs, 
and the WST-8 assay was then performed. LPS did not affect the viable cell number of hippocampus-derived 
NSCs in the presence or absence of EGF, indicating that LPS did not directly affect the proliferation of the NSCs. 
 The effects of COX inhibitors on LPS-induced impairment of the newborn cell survival were examined in 
the dentate gyms. The number of BrdU-labeled cells in the SGZ and the  GCL. 7 days after BrdU injection was 
analyzed. The systemic injection of indomethacin (10 mg/kg), a non-selective COX inhibitor, and NS-398 (10  mg/ 
kg), a selective COX-2 inhibitor, completely protected LPS-induced reduction in BrdU-labeled cell number in the 
dentate gyms. In contrast, LPS-induced reduction in BrdU-labeled cell number was unaffected by the pretreatment 
with SC-560 (12  mg/kg), a selective COX-1 inhibitor. Furthermore, the i.c.v. injection of NS-398 (1  pg/10 
mouse) also completely protected against LPS-induced decrement in BrdU-labeled cell number. 
 We investigated the expression of COX-2 in the dentate gyms of mice with or without LPS treatment. Seven hrs 
after LPS injection (1 mg/kg), it significantly increased the number of COX-2-positive cells in the GCL and the 
ML. Even seven days after  LPS injection (1 mg/kg), it caused the moderate, but significant increase in the number 
of COX-2-positive cells in the GCL, but not in the ML. The immunohistochemistry of double-immunostaing for 
COX-2 and specific cell type markers revealed that the majority of COX-2-positive cells in the GCL co-expressed 
NeuN and the small portion of COX-2-positive cells in the GCL co-expressed DCX. It was noteworthy that 
DCX- and COX-2-double positive cells exist only in the GCL, but not in the SGZ. Next, we examined whether the 
microglia expresses COX-2 in the presence or absence of LPS by staining  CD11, which is a maker protein of both 
the activated and resting microglia. We observed that the number of  CD 11-positivecells did not alter after LPS 
treatment, however, its intensity seem to increase by LPS treatment. We found that the majority of microglia did not
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express the COX-2 protein in the SGZ, GCL and ML of both control and LPS-treated mice. 
 To identify the molecular candidates mediating LPS-induced impairment of the newborn cell survival, we 
utilized the embryonic hippocampus-derived NSCs, which enable us to evaluate the direct actions of drugs. Since 
 PGD2,  15d-PGJ2 and PGE2, are not only known to be produced by COX-2-mediated arachidonic acid pathways 
and but also reported to show the apoptosis-inducing activity, we tested whether these compounds as well as LPS 
would cause the cell death using a TUNEL method.  PGD2,  15d-PGJ2 and PGE2 increased the cell death of the 
NSCs in a concentration-dependent manner. Among PGs used in this experiment,  15d-PGJ, exhibited the most 
potent activity inducing cell death in the NSCs. LPS showed a moderate, but significant increment in the cell death 
only at  I  .ig/ml, but not at other concentrations. Taken together, these data suggest that PGE2,  PGD2, as well as its 
metabolite  15d-PGJ2, are feasible candidates mediating the LPS action in the neurogenesis. 
 In conclusion, the present study confirmed the LPS suppressed the neurogenesis in the adult mouse  DG by 
impairing the newborn cell survival presumably via  COX-2-mediated PGD2,  15d-PGJ2 and PGE2 production (Fig. 
 1). The systemic injection of LPS affects the survival of NSCs due to the activation of COX-2 in LPS-responsive 
mature granule cells (Fig.  1). These cells release prostaglandins in response to  neuroinflammation (Fig. 1). The 
released  PGD2, 15d-PGJ2 and  PGE2 promote the cell death, resulting in the suppression of newborn cells survival.
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Fig. 1: The speculated diagram showing that LPS suppresses the neurogenesis in the adult mouse DG by impairing 
 the newborn cell survival presumably via COX-2-mediated  PGD2 and 15d-PGJ, production.
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審 査 結 果 の 要 旨
神経幹細胞 は 自己複 製能 と神経細胞や グ リア細胞 への分化能 を有す る細胞で あるが,発 生期 のみな ら
ず成体脳 にも存在す るこ とが明 らかにな り,そ の うちの海馬 歯状 回で は,毎 日数千 の新 生細胞 が生 まれ
てい る と考 え られてい る。神経幹細胞の 自己複製能や 分化能,さ らに新生 した細胞の生存能な どは,虚 血,
てんかん,神 経炎症 な どで影響 を受 けることが知 られ てお り,こ れ らの機能 を調節す るこ とが出来れば,
多 くの中枢神経 系の疾 病 を治療す るこ とが可能 にな る。一方,バ クテ リアの内毒 素であ る リポポ リサ ッ
カライ ド(上PS)は 神経 炎症 を引き起 こ して神経新生 に影響 を与 えることが報告 され ている。すな わち,
LPSは 神経新生 を抑制 す るが,そ の詳細 なメカニズムについては不 明な点 が多 い。そ こで,本 論文で は
成体マ ウスの歯状 回における神経新生 がLPS処 理 によって どの よ うに影響 され るか を検討 し,そ のメカ
ニズムについて も解析 を加 えた。
LPSを マ ウスに投 与 し,そ の5時 間後 に増殖 マー カーのプ ロモデオキ シウリジ ン(BrdU)を 投与 した。
その2時 間後 に脳 をサ ンプ リング し,BrdUの 取 り込み を調 べたが,影 響 は認 め られな かった。一方,
LPS投 与後7日 目あるい は21日 目のBrdU取 り込み によ り,神 経幹 細胞 の分化 あ るい は生存 を検討 した
ところ,LPS投 与マ ウスの歯状 回 にお いてBrdU取 り込み を示す 細胞数 の減少 が見 られ た。 また,LPS
処理 に よ り,TUN肌 一陽性細胞 が増加 してい るこ とも示 され た。す なわち,LPSは 神経 幹細胞か ら新生
した細 胞の生存 を抑制 している ことが示 され た。一方,正PSは 神経幹細胞 か らの神経細胞 やアス トロサ
イ トへの分化 には影響 を与 えなかった。 した がって,LPSは 神経幹細胞 か ら生 まれ た未熟な新生細胞 の
生存を抑制す る もの と考 え られた。次に,'ηv'伽 で海馬由来 の神経 幹細胞 の生存 に及 ぼすLPSの 作用 に
っいて検討 を加 えたが,LPSは 抑制 を示 さなか った。 した がって,エPSの 作用 は神経 幹細胞 に直接影響
を与 えてい るのではな く,他 の細胞 を介 した間接 的な作用 と考 え られ た。LPSの 作用 はNFKBを 介 して
シ クロオキシ ゲナーゼ ー2(COX-2)を 発現 させ,プ ロスタノイ ドの生合成 を高め るこ とが知 られ てい る。
そ こで,LPSに よる新 生細胞 の生存 抑制 にお よぼすCOX-2の 介在 につい て検討 を した ところ,非 特 異
的COX阻 害薬のイ ン ドメタシ ンやCOX-2特 異的阻害薬 のNS-398に よって生存 抑制 の回復 が見 られ,
COX-2の 介在 が考 え られ た。次 に,歯 状 回でCOX-2を 発現 してい る細胞種 を検 討 した ところ,ミ ク ロ
グ リアで はな く,成 熟 した神経細胞 の一部 であった。 さらに,COX-2に よって生 成す る どの種 のプ ロス
タノイ ドが細胞 の生存抑制 に関与す るのかを,加v'砌 の神経幹細胞 を用い て検討 した ところ,プ ロスタ
グランジンD2,そ の非酵素的代謝物 の15一 デオ キシ ープ ロスタグラ ンジンJ,お よびプ ロス タグ ランジ ン
E.に 抑 制活性 が認 め られ た。す なわち,こ れ らのプ ロス タノイ ドを介 してLPSが 神経幹細胞 か らの新 生
細胞 の生存 を抑制 してい るこ とが考 え られ た。以上 のよ うに,本 研究 は神経炎症 を引き起 こすLPSの 神
経幹細胞機能 に及ぼす作用 の一端 を明 らか に した極 めて貴重な ものである。
したがって,本 論文は博 士(薬 学)の 学位論文 として合格 と認める。
